Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

September 01, 1996; Volume 50,Issue 3
  • You have access
    Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
    D Y Ryu, P E Levi, P Fernandez-Salguero, F J Gonzalez and E Hodgson
    Molecular Pharmacology September 1996, 50 (3) 443-446;
  • You have access
    Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes.
    H Matthes, E P Seward, B Kieffer and R A North
    Molecular Pharmacology September 1996, 50 (3) 447-450;
  • You have access
    Structural requirements of sphingosylphosphocholine and sphingosine-1-phosphate for stimulation of activator protein-1 activity.
    A Berger, R Bittman, R R Schmidt and S Spiegel
    Molecular Pharmacology September 1996, 50 (3) 451-457;
  • You have access
    Pharmacological properties of gamma-aminobutyric acidA receptors from acutely dissociated rat dentate granule cells.
    J Kapur and R L Macdonald
    Molecular Pharmacology September 1996, 50 (3) 458-466;
  • You have access
    A fully active nonglycosylated V2 vasopressin receptor.
    G Innamorati, H Sadeghi and M Birnbaumer
    Molecular Pharmacology September 1996, 50 (3) 467-473;
  • You have access
    Role of heme in cytochrome P450 transcription and function in mice treated with lead acetate.
    R Jover, R L Lindberg and U A Meyer
    Molecular Pharmacology September 1996, 50 (3) 474-481;
  • You have access
    BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
    Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
    Molecular Pharmacology September 1996, 50 (3) 482-492;
  • You have access
    Constitutive activation of a phosphoinositidase C-linked G protein in murine fibroblasts decreases agonist-stimulated Ca2+ mobilization.
    L A Lobaugh, B Eisfelder, K Gibson, G L Johnson and J W Putney
    Molecular Pharmacology September 1996, 50 (3) 493-500;
  • You have access
    D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.
    M L Handel, C K Watts, S Sivertsen, R O Day and R L Sutherland
    Molecular Pharmacology September 1996, 50 (3) 501-505;
  • You have access
    Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
    D Zhu, M E Cardenas and J Heitman
    Molecular Pharmacology September 1996, 50 (3) 506-511;
  • You have access
    Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
    Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
    Molecular Pharmacology September 1996, 50 (3) 512-521;
  • You have access
    Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism.
    H Arai and J A Escobedo
    Molecular Pharmacology September 1996, 50 (3) 522-528;
  • You have access
    Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
    A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
    Molecular Pharmacology September 1996, 50 (3) 529-537;
  • You have access
    Trans-activation by the human aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator proteins: direct interactions with basal transcription factors.
    J C Rowlands, I J McEwan and J A Gustafsson
    Molecular Pharmacology September 1996, 50 (3) 538-548;
  • You have access
    Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
    H Yu, J J Cai and H C Lee
    Molecular Pharmacology September 1996, 50 (3) 549-555;
  • You have access
    Okadaic acid potentiates 3-methylcholanthrene-induced CYP2A8 gene expression in primary cultures of Syrian hamster hepatocytes: possible involvement of activator protein-1.
    M Tohkin, K Kurose and M Fukuhara
    Molecular Pharmacology September 1996, 50 (3) 556-564;
  • You have access
    Ontogeny and hormonal basis of male-dominant rat hepatic sulfotransferases.
    L Liu and C D Klaassen
    Molecular Pharmacology September 1996, 50 (3) 565-572;
  • You have access
    Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
    E Eliasson and J G Kenna
    Molecular Pharmacology September 1996, 50 (3) 573-582;
  • You have access
    Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
    J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
    Molecular Pharmacology September 1996, 50 (3) 583-591;
  • You have access
    Quinone thioether-mediated DNA damage, growth arrest, and gadd153 expression in renal proximal tubular epithelial cells.
    J K Jeong, J L Stevens, S S Lau and T J Monks
    Molecular Pharmacology September 1996, 50 (3) 592-598;
  • You have access
    The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors.
    L Y Li and K J Chang
    Molecular Pharmacology September 1996, 50 (3) 599-602;
  • You have access
    Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
    F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
    Molecular Pharmacology September 1996, 50 (3) 603-609;
  • You have access
    Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells.
    J L Moran, D Siegel, X M Sun and D Ross
    Molecular Pharmacology September 1996, 50 (3) 610-615;
  • You have access
    N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.
    K Liliom, R Bittman, B Swords and G Tigyi
    Molecular Pharmacology September 1996, 50 (3) 616-623;
  • You have access
    Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.
    N L Diehl, J C Kermode and S M Shreeve
    Molecular Pharmacology September 1996, 50 (3) 624-630;
  • You have access
    Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors.
    J Zhong, V K Gribkoff and P B Molinoff
    Molecular Pharmacology September 1996, 50 (3) 631-638;
  • You have access
    Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives.
    H Grosfeld, D Barak, A Ordentlich, B Velan and A Shafferman
    Molecular Pharmacology September 1996, 50 (3) 639-649;
  • You have access
    The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
    B Chieng, M Connor and M J Christie
    Molecular Pharmacology September 1996, 50 (3) 650-655;
  • You have access
    Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
    Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
    Molecular Pharmacology September 1996, 50 (3) 656-661;
  • You have access
    Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor.
    P Chidiac, S Nouet and M Bouvier
    Molecular Pharmacology September 1996, 50 (3) 662-669;
  • You have access
    Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
    K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
    Molecular Pharmacology September 1996, 50 (3) 670-678;
  • You have access
    125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
    Molecular Pharmacology September 1996, 50 (3) 679-686;
  • You have access
    Mercury binding site on Na+/K(+)-ATPase: a cysteine in the first transmembrane segment.
    X Wang and J D Horisberger
    Molecular Pharmacology September 1996, 50 (3) 687-691;
  • You have access
    Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
    K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
    Molecular Pharmacology September 1996, 50 (3) 692-699;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 50, Issue 3
1 Sep 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Read
Loading
  • Proteomic Analysis of GPCR Cell Biology
  • Phosphoproteomic Analysis of cAMP-Dependent Pathways
  • Phosphoproteomic Identification of Signaling Pathways
  • How Many G Protein-Coupled Receptors are Drug Targets?
  • Characterization of GRD and LCCH3 from Human Louse
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics